CRL Profile
Charles River Laboratories International, Inc., headquartered in Wilmington, Massachusetts, is a leading non-clinical contract research organization (CRO) renowned for its comprehensive array of drug discovery and development services across global markets. Established in 1947, the company operates through three distinct segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
The RMS segment of Charles River Laboratories specializes in the production and distribution of research models, including rodent strains and purpose-bred rats and mice. Beyond model provision, RMS offers a suite of supporting services such as genetically engineered models, insourcing solutions, and diagnostic services, crucial for research and screening non-clinical drug candidates.
In the realm of drug discovery and safety assessment, the DSA segment provides a comprehensive range of early-stage in vivo and in vitro services. These include target identification, validation of novel compounds, and preparation of therapeutic candidates for subsequent safety evaluations. DSA further excels in toxicology, pathology, safety pharmacology, bioanalysis, and pharmacokinetics services, pivotal for advancing drug development pipelines.
Charles River Laboratories' Manufacturing segment contributes significantly to pharmaceutical and consumer product industries by offering specialized in vitro testing methods. These encompass rigorous quality control assessments for sterile and non-sterile pharmaceuticals, as well as biologics testing outsourced by biotechnology and pharmaceutical companies. The company's avian vaccine services also play a critical role in supplying specific-pathogen-free fertile chicken eggs and chickens, alongside diagnostic products essential for vaccine manufacturing.
With a global footprint spanning the United States, Europe, Canada, the Asia Pacific, and other international markets, Charles River Laboratories International continues to innovate and expand its capabilities in non-clinical research and development services, reinforcing its position as a trusted partner in advancing pharmaceutical and biotechnology innovations.
|
